Reference Genotype Strain 19 S. enterica serovar Typhimurium SL1344 ciproﬂoxacin - selected MDR Cyc T L664 ramA : : aph L664 ramA : : aph / pTRChisA : : ramA SL1344 ramR : : aph S SL1344 ciproﬂoxacin - selected MDR Cyc L905 ramA : : aph L905 ramA : : aph / pTRChisA : : ramA pre-therapy clinical isolate L3 ramA : : aph L3 ramA : : aph / pTRChisA : : ramA L3 ramR : : aph 2 months post-therapy clinical isolate L10 ramA : : aph SL1344 L664 L982 L876 L1007 L905 L981 L990 L3 L993 L873 L1008 L10 L994 this study this study this study this study this study this study this study 7,20,28 this study this study this study 7,20,28 this study Measurement of efﬂux by mutants and clinical isolates Accumulation of ciproﬂoxacin , chloramphenicol and tetracycline has been described previously for the clinical isolates .

Efﬂux was measured in the absence and presence of two inhibitors of efﬂux , Phe - Arg - b - naphthylamide ( PAbN ; 40 mg / L ) ( Sigma ) and carbonyl cyanide m - chlorophenylhydrazone ( CCCP ; this study 7,20,28 this study this study 14 this study this study this study this study this study L10 ramA : : aph / pTRChisA : : ramA 5 months post-therapy clinical isolate L18 ramA : : aph L18 ramA : : aph / pTRChisA : : ramA DT104 S / 92145 ramR : : aph SL1344 ramR : : aph / pUC19 - SL 1344 - ramR SL1344 ramR : : aph / pUC19 - L 3 - ramR L3 ramR : : aph / pUC19 - L 3 - ramR L3 ramR : : aph / pUC19 - SL 1344 - ramR SL1344 ramR : : aph / pUC19 - L 664 - ramR L874 L18 L995 L875 L1005 L1012 L1013 L1014 L1015 L1016 30 mM ) ( Sigma ) .

Brieﬂy , donor P22 SL1344 phage was grown on Salmonella Typhimurium acrB : : aph , SL1344 tolC : : aph , SL1344 ramA : : aph , SL1344 marA : : aph , SL1344 soxS : : aph or S / 92145 ramR : : aph , and transductants selected on kanamycincontaining agar plates .

Primers used in this study Reverse primer Forward primer T -- PCR Primers used for R ramA ramR AGCTTCCGTTCACGCACGTA CATAAATCGCGCAATTCGGG TCCGCTCAGGTTATCGACAC TTTCGCGACCAAAGATGAGC Check primers for transductions ramR AGGCCAGCAGTGTTCGGTAA TTGACATTCACCGTTGCGAC Primers for mutant detection ramA ramR ramA -- ramR intergenic region CGGCGCGCTGGAATATTA AGGCCAGCAGTGTTCGGTAA TTGTCTTCACTCTTCGGACG GCTTATTGCTGTTGCCGT TTGACATTCACCGTTGCGAC ATCGTGTCGATAACCTGAGC Table 3 .

Effect on phenotype of inactivating and complementing various genes in ciproﬂoxacin - selected MDR mutants ( L664 and L905 ) Fold change in gene expression compared with SL1344 MIC ( mg / L ) Genotype a CIP NAL TET TRI CYC Strain acrB tolC ramA CHL SL1344 wild - type MDR Cyc 2 1 S 1 1 1 0.015 0.12 2 T L664 marA : : aph L664 ramA : : aph L982 pTRCramA L982 pTRCramAþIPTG MDR Cyc S L905 marA : : aph L905 ramA : : aph L981 pTRCramA L981 pTRCramA þIPTG 8 4 T 4.6 1.4 3.4 L664 L1008 L982 L876 L876 0.12 0.12 0.03 0.5 0.5 1 1 16 16 4 16 32 4 T 8 4 2 S 0.12 0.25 2 T 256 256 2.4 5.9 1.4 3.4 2.6 4 19.1 16 T L905 L1009 L981 L990 L990 0.5 0.5 0.12 0.25 0.12 0.12 1 8 256 256 8 256 256 3.5 1.1 S 2.2 32 32 4 32 64 4 S 0.03 0.5 0.5 2 S 8 S 1 2.9 5.1 2.2 13.9 32 S 2.9 CIP , ciproﬂoxacin ; NAL , nalidixic acid ; CHL , chloramphenicol ; TET , tetracycline ; TRI , triclosan ; CYC , cyclohexane ; S , susceptible ; T , tolerant .

Effect on phenotype of inactivating and complementing various genes in pre - and post-ciproﬂoxacin therapy MDR clinical isolates Fold change in gene expression compared with SL1344 MIC ( mg / L ) Genotype a CYC TRI TET NAL CIP acrB Strain CHL tolC ramA 1 2 0.12 0.015 wild - type SL1344 1 S 2 1 1 0.8 S 2 1.1 3.8 0.5 0.5 0.5 2 1 2 0.06 0.06 0.06 0.25 0.12 0.12 0.06 0.015 0.003 0.015 0.015 0.015 0.015 0.007 pre-therapy L3 ramA : : aph L3 S 1 0.5 2 8 L993 L873 L873 L1008 L1015 L1014 L993 pTRChisA : : ramA L993 pTRChisA : : ramAþIPTG L3 ramR : : aph L1008 pUC19 SL1344 ramR L1008 pUC19 L3 ramR S 2 3.2 5.9 1.3 9.3 15.7 1.6 3 1.4 4 S S 2 2 0.9 S 1 2 2 1 2 S 1 1.6 5.4 4 L10 2 months post-therapy L10 ramA : : aph S 16 0.5 8 16 4 2 0.03 0.03 0.03 0.06 3.1 0.5 4 8 0.06 2 2 L994 L874 L874 S 1 L994 pTRChisA : : ramA L994 pTRChisA : : ramA þIPTG 4.6 3.2 5.5 4 1.3 S 8 S 17.1 3.3 S 16 4 16 32 16 2 16 8 16 64 16 4 1 5 months post-therapy L18 ramA : : aph L18 3.3 1.4 5.6 16 0.5 8 16 0.25 0.06 0.25 0.5 0.06 0.03 0.12 0.25 L995 L875 L875 L1007 L1012 L1016 L1013 0.06 1 1 0.25 0.12 0.5 1 S S 4.4 1.7 3.6 1.5 4.8 6.1 1.5 L995 pTRChisA : : ramA L995 pTRChisA : : ramA þIPTG SL1344 ramR : : aph L1007 pUC19 SL1344 ramR L1007 pUC19 L664 ramR L1007 pUC19 L3 ramR S 20.7 1.4 T 8 S 2 8 8 T 8 T 4 4 8 CIP , ciproﬂoxacin ; NAL , nalidixic acid ; CHL , chloramphenicol ; TET , tetracycline ; TRI , triclosan ; CYC , cyclohexane ; S , susceptible ; T , tolerant .

Trans R Soc

